流行性脑脊髓膜炎(以下简称流脑)为急性呼吸道传染病,在磺胺药未发明前,病死率高达50—70％,但自该药应用到临床后,病死率间于5—10％,尤在1958年后降低到3—5％,甚至更低,故被国内外公认为治疗流脑的特效药物,并以磺胺嘧啶为佳,不易产生耐药。Smith曾谓:未曾有过令人信服的耐药病例。国内自1960年上海顾松鹤等首次报告6例耐磺胺嘧啶的流脑,引起了大家的重视。1962年李景洲等又报告6例。我院1962—1963年间也发现了16例,且在 Epidemic cerebrospinal meningitis (hereinafter referred to as meningitis) is an acute respiratory disease, sulfa drugs before the invention, the fatality rate as high as 50-70%, but since the drug is applied to the clinic, the mortality between 5-10% , Especially after 1958 to reduce to 3-5%, or even lower, it is recognized at home and abroad for the treatment of meningitis-specific drugs, and sulfadiazine is better, not easy to produce resistance. Smith once said: There have been no convincing cases of resistance. For the first time since 1960, Shanghai Gu Songhe et al. Reported 6 cases of sulfadiazine-resistant meningitis, which aroused people’s attention. In 1962, Li Jingzhou and other reports of 6 cases. Our hospital also found 16 cases between 1962-1963, and at that time